Aurinia Pharmaceuticals AUPH Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's accrued expenses and other liabilities?
- Aurinia Pharmaceuticals (AUPH) reported accrued expenses and other liabilities of -$5.59M in Q1 2026.
- How has Aurinia Pharmaceuticals's accrued expenses and other liabilities changed year-over-year?
- Aurinia Pharmaceuticals's accrued expenses and other liabilities increased by 76.1% year-over-year, from -$23.41M to -$5.59M.
- What is the long-term trend for Aurinia Pharmaceuticals's accrued expenses and other liabilities?
- Over 2 years (2022 to 2024), Aurinia Pharmaceuticals's accrued expenses and other liabilities has grown at a 199.0% compound annual growth rate (CAGR), from $1.49M to $13.33M.